File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Opioid MOP receptor agonists in late-stage development for the treatment of postoperative pain

TitleOpioid MOP receptor agonists in late-stage development for the treatment of postoperative pain
Authors
Issue Date1-Nov-2022
PublisherTaylor and Francis Group
Citation
Expert Opinion on Pharmacotherapy, 2022, v. 23, n. 16, p. 1831-1843 How to Cite?
Abstract

Introduction: Opioids remain important in postoperative analgesia although, the focus is on using them as part of multimodal regimens where it is not possible to avoid their use completely. The development of novel agents with more favorable adverse effect profiles may increase safety whilst maintaining efficacy. Areas covered: This article reviews the clinical trials for opioids in late-stage development. The objective of this narrative review is to evaluate the pharmacokinetic properties, safety, tolerability, and analgesic efficacy of these agents in the management of postoperative pain. Expert opinion: Oliceridine appears to be an effective and potentially safer mu opioid receptor agonist. Its main advantages are a relatively fast onset with reduced respiratory depression, nausea, and vomiting. Cebranopadol is an agonist at multiple opioid receptors, of which mu opioid and nociceptin/orphanin FQ peptide (NOP) receptor are most significant. It is an oral drug that appears to have efficacy in neuropathic pain, with reduced respiratory depression and abuse potential. Lastly, morphine-6-glucuronide is an active metabolite of morphine with a slower onset than its parent compound. It has failed to demonstrate appreciable benefit in the context of postoperative analgesia.


Persistent Identifierhttp://hdl.handle.net/10722/328334
ISSN
2023 Impact Factor: 2.5
2023 SCImago Journal Rankings: 0.687
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorQiu, Q-
dc.contributor.authorChew, JC-
dc.contributor.authorIrwin, MG-
dc.date.accessioned2023-06-28T04:42:31Z-
dc.date.available2023-06-28T04:42:31Z-
dc.date.issued2022-11-01-
dc.identifier.citationExpert Opinion on Pharmacotherapy, 2022, v. 23, n. 16, p. 1831-1843-
dc.identifier.issn1465-6566-
dc.identifier.urihttp://hdl.handle.net/10722/328334-
dc.description.abstract<p> Introduction: Opioids remain important in postoperative analgesia although, the focus is on using them as part of multimodal regimens where it is not possible to avoid their use completely. The development of novel agents with more favorable adverse effect profiles may increase safety whilst maintaining efficacy. Areas covered: This article reviews the clinical trials for opioids in late-stage development. The objective of this narrative review is to evaluate the pharmacokinetic properties, safety, tolerability, and analgesic efficacy of these agents in the management of postoperative pain. Expert opinion: Oliceridine appears to be an effective and potentially safer mu opioid receptor agonist. Its main advantages are a relatively fast onset with reduced respiratory depression, nausea, and vomiting. Cebranopadol is an agonist at multiple opioid receptors, of which mu opioid and nociceptin/orphanin FQ peptide (NOP) receptor are most significant. It is an oral drug that appears to have efficacy in neuropathic pain, with reduced respiratory depression and abuse potential. Lastly, morphine-6-glucuronide is an active metabolite of morphine with a slower onset than its parent compound. It has failed to demonstrate appreciable benefit in the context of postoperative analgesia. <br></p>-
dc.languageeng-
dc.publisherTaylor and Francis Group-
dc.relation.ispartofExpert Opinion on Pharmacotherapy-
dc.titleOpioid MOP receptor agonists in late-stage development for the treatment of postoperative pain-
dc.typeArticle-
dc.identifier.doi10.1080/14656566.2022.2141566-
dc.identifier.hkuros344710-
dc.identifier.volume23-
dc.identifier.issue16-
dc.identifier.spage1831-
dc.identifier.epage1843-
dc.identifier.eissn1744-7666-
dc.identifier.isiWOS:000879983900001-
dc.identifier.issnl1465-6566-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats